NASDAQ:PAVM - PAVmed Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.27 -0.01 (-0.78 %) (As of 09/19/2018 03:07 PM ET)Previous Close$1.28Today's Range$1.26 - $1.2852-Week Range$0.87 - $8.13Volume1,709 shsAverage Volume391,703 shsMarket Capitalization$35.57 millionP/E Ratio-2.44Dividend YieldN/ABeta-0.6 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York. Receive PAVM News and Ratings via Email Sign-up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical SymbolNASDAQ:PAVM CUSIPN/A Webwww.pavmed.com Phone212-949-4319 Debt Debt-to-Equity RatioN/A Current Ratio2.38 Quick Ratio2.38 Price-To-Earnings Trailing P/E Ratio-2.44 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value($0.22) per share Price / Book-5.77 Profitability EPS (Most Recent Fiscal Year)($0.52) Net Income$-9,510,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-171.55% Miscellaneous Employees5 Outstanding Shares26,540,000Market Cap$35.57 million PAVmed (NASDAQ:PAVM) Frequently Asked Questions What is PAVmed's stock symbol? PAVmed trades on the NASDAQ under the ticker symbol "PAVM." How were PAVmed's earnings last quarter? PAVmed Inc (NASDAQ:PAVM) posted its earnings results on Tuesday, August, 14th. The company reported ($0.27) EPS for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.16. View PAVmed's Earnings History. When is PAVmed's next earnings date? PAVmed is scheduled to release their next quarterly earnings announcement on Wednesday, November, 21st 2018. View Earnings Estimates for PAVmed. What price target have analysts set for PAVM? 1 brokers have issued 1 year price objectives for PAVmed's stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate PAVmed's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 293.7% from the stock's current price. View Analyst Price Targets for PAVmed. What is the consensus analysts' recommendation for PAVmed? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PAVmed. Who are some of PAVmed's key competitors? Some companies that are related to PAVmed include Alphatec (ATEC), STRATA Skin Sciences (SSKN), Sensus Healthcare (SRTS), Motus GI (MOTS), Restoration Robotics (HAIR), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), CAS Medical Systems (CASM), Repro-Med Systems (REPR), Obalon Therapeutics (OBLN), Neovasc (NVCN), iCAD (ICAD), Spectral Medical (EDTXF), Pro-Dex (PDEX) and Interpace Diagnostics Group (IDXG). Who are PAVmed's key executives? PAVmed's management team includes the folowing people: Dr. Lishan Aklog M.D., Chairman & CEO (Age 52)Mr. Dennis M. McGrath CPA, Exec. VP, CFO & Sec. (Age 61)Dr. Brian J. deGuzman M.D., Chief Medical Officer (Age 53)Mr. Shaun M. O'Neil, Chief Commercial Officer Has PAVmed been receiving favorable news coverage? News stories about PAVM stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. PAVmed earned a coverage optimism score of 0.18 on Accern's scale. They also gave news stories about the company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for PAVmed. Who are PAVmed's major shareholders? PAVmed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Levin Capital Strategies L.P. (1.24%). Company insiders that own PAVmed stock include Dennis M Mcgrath, Ira Scott Greenspan, Joshua R Lamstein and Lishan Aklog. View Institutional Ownership Trends for PAVmed. Which institutional investors are buying PAVmed stock? PAVM stock was acquired by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P.. Company insiders that have bought PAVmed stock in the last two years include Dennis M Mcgrath, Joshua R Lamstein and Lishan Aklog. View Insider Buying and Selling for PAVmed. How do I buy shares of PAVmed? Shares of PAVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is PAVmed's stock price today? One share of PAVM stock can currently be purchased for approximately $1.27. How big of a company is PAVmed? PAVmed has a market capitalization of $35.57 million. The company earns $-9,510,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. PAVmed employs 5 workers across the globe. How can I contact PAVmed? PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company can be reached via phone at 212-949-4319 or via email at [email protected] MarketBeat Community Rating for PAVmed (NASDAQ PAVM)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 90 (Vote Outperform)Underperform Votes: 104 (Vote Underperform)Total Votes: 194MarketBeat's community ratings are surveys of what our community members think about PAVmed and other stocks. Vote "Outperform" if you believe PAVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAVM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/19/2018 by MarketBeat.com StaffFeatured Article: What strategies should day traders use to execute a trade?